Ultragenyx Pharmaceutical Inc. (RARE)

Finanzdaten der Ultragenyx Pharmaceutical Inc.-Aktie (RARE)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	29.92% 127.39	98.05	108.31	100.50	103.35
Operating Expenses	2.59% 249.44	243.15	256.27	254.60	248.98
Benefits Costs and Expenses	1.08% 254.28	257.05	267.40	263.97	256.63
Costs And Expenses	1.08% 254.28	257.05	267.40	263.97	256.63
Operating Income/Loss	15.88% -122.05	-145.10	-147.96	-154.10	-145.63
Income/Loss From Continuing Operations Before Tax	20.19% -126.89	-159.00	-159.10	-163.48	-153.28
Income Tax Expense/Benefit	669.54% -3.702	0.65	0.732	0.495	-1.451
Income/Loss From Continuing Operations After Tax	22.84% -123.19	-159.65	-159.83	-163.97	-151.83
Net Income/Loss	22.84% -123.19	-159.65	-159.83	-163.97	-151.83
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	96.43% 2.5561	71.66	70.90	70.37	0.0802
Diluted Average Shares	96.43% 2.5561	71.66	70.90	70.37	0.0802
Basic Earnings Per Share	35.43% -1.44	-2.23	-2.25	-2.33	-2.16
Diluted Earnings Per Share	35.43% -1.44	-2.23	-2.25	-2.33	-2.16
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-